Company profile
Bright Minds Biosciences Inc.
NASDAQ: DRUG · Healthcare · Biotechnology
Canadian filerHQ New York, NYCIK 0001827401Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 47
v0.1 · 5/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.1M
Employees
26
as of 2026-09-12
Market cap
$618.4M
as of 2026-09-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$2.1M-2.8M CAD2024
Total assets$4.5M6.1M CAD2024
Liabilities$421.0k568.3k CAD2024
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bright Minds Biosciences Inc.’s financial profile?
Bright Minds Biosciences Inc. earned -$2.1M in FY2024 net income.
Peers · Healthcare
Annexon, Inc.——BlossomHill Therapeutics, Inc.——Nuvectis Pharma, Inc.——Eikon Therapeutics, Inc. Common Stock——Tectonic Therapeutic, Inc.——Zura Bio Limited——Key facts
CEOIan McDonald
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York, NY
ExchangeNASDAQ: DRUG
Employees26
IPO date2021-03-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.